These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33934550)

  • 1. Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals' preferences.
    Dankers M; Nelissen-Vrancken MHJMG; Hart BH; Lambooij AC; van Dijk L; Mantel-Teeuwisse AK
    Pharmacol Res Perspect; 2021 May; 9(3):e00750. PubMed ID: 33934550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
    Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
    Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial.
    Hermanns N; Ehrmann D; Schall S; Maier B; Haak T; Kulzer B
    Diabet Med; 2017 Aug; 34(8):1084-1091. PubMed ID: 28257159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes in Adults and Glycemic Outcomes.
    Alkhiari R; Alzayer H; Aljazeeri J; Vanniyasingam T; Punthakee Z
    Can J Diabetes; 2018 Apr; 42(2):158-162. PubMed ID: 28662968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus.
    Bonke FC; Donnachie E; Schneider A; Mehring M
    Diabetologia; 2016 Feb; 59(2):286-93. PubMed ID: 26518684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.